Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(3.53)
# 892
Out of 5,008 analysts
51
Total ratings
38.46%
Success rate
11.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $22.29 | - | 3 | Sep 8, 2025 | |
| LEGN Legend Biotech | Assumes: Overweight | $55 → $66 | $31.41 | +110.12% | 1 | Aug 27, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $39.50 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $46.95 | +104.47% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $10.17 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $102.17 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.41 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.51 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $18.17 | -28.40% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $4.31 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $70.62 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $87.17 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $40.87 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.29 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $34.22 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $152.21 | +91.84% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $410.28 | -9.82% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.93 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.67 | - | 1 | May 30, 2017 |
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.29
Upside: -
Legend Biotech
Aug 27, 2025
Assumes: Overweight
Price Target: $55 → $66
Current: $31.41
Upside: +110.12%
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $39.50
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $46.95
Upside: +104.47%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.17
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $102.17
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.41
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.51
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $18.17
Upside: -28.40%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.31
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $70.62
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $87.17
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $40.87
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.29
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $34.22
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $152.21
Upside: +91.84%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $410.28
Upside: -9.82%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.93
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.67
Upside: -